Elsevier

Fertility and Sterility

Volume 101, Issue 2, February 2014, Pages 366-378.e14
Fertility and Sterility

Original article
International Committee for Monitoring Assisted Reproductive Technology: world report on assisted reproductive technology, 2005

https://doi.org/10.1016/j.fertnstert.2013.10.005Get rights and content
Under an Elsevier user license
open archive

Objective

To analyze information on assisted reproductive technology (ART) performed worldwide and trends in outcomes over successive years.

Design

Cross-sectional survey on access, effectiveness, and safety of ART procedures performed in 53 countries during 2005.

Setting

A total of 2,973 clinics from national and regional ART registries.

Patient(s)

Infertile women and men undergoing ART globally.

Intervention(s)

Collection and analysis of international ART data.

Main Outcome Measure(s)

Number of cycles performed by country and region, including pregnancies, single and multiple birth rates, and perinatal mortality.

Result(s)

Overall, 1,052,363 ART procedures resulted in an estimated 237,315 babies born. The availability of ART varied by country from 15 to 3,982 cycles per million of population. Of all initiated fresh cycles, 62.9% were intracytoplasmic sperm injection. The overall delivery rate per fresh aspiration was 19.6% and for frozen embryo transfer 17.4%, with a cumulative delivery rate of 23.9%. With wide regional variations, single embryo transfer represented 17.5% of cycles, and the proportion of deliveries with twins and triplets from fresh transfers was 23.6% and 1.5%, respectively.

Conclusion(s)

Systematic collection and dissemination of international ART data allows patients, health professionals, and policy makers to examine and compare the impact of reproductive strategies or lack of them as markers of reproductive health.

Key Words

ART
assisted reproductive technology
registry
outcomes
multiple births
public health
IVF

Cited by (0)

F.Z.-H. has nothing to disclose. R.M. has nothing to disclose. O.I. has nothing to disclose. G.D.A. has received research funding from Auxogyn and holds stock in Advanced Reproductive Care and XDhealth. J.d.M. has nothing to disclose. K.G.N. has nothing to disclose. E.A.S. has nothing to disclose.